Buprenorphine: prospective novel therapy for depression and PTSD
| Autor: | Shoshana Eitan, Caitlin A Madison |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent κ-opioid receptor Stress Disorders Post-Traumatic 03 medical and health sciences Depressive Disorder Treatment-Resistant Young Adult 0302 clinical medicine medicine Humans Prospective Studies Psychiatry Applied Psychology Post-traumatic stress disorder (PTSD) Endogenous opioid Aged Depressive Disorder Major business.industry Chronic pain Middle Aged medicine.disease Antidepressive Agents Naltrexone 030227 psychiatry Buprenorphine Analgesics Opioid Psychiatry and Mental health Drug Combinations Opioid Major depressive disorder Antidepressant Female business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Psychological medicine. 50(6) |
| ISSN: | 1469-8978 0033-2917 |
| Popis: | BackgroundDepression and post-traumatic stress disorder (PTSD) are leading causes of disability and loss of life by suicide. Currently, there are less than satisfactory medical solutions to treat these mental disorders. Here, we explore recent preclinical and clinical studies demonstrating the potential of using buprenorphine to treat major depressive disorder, treatment-resistant depression, and PTSD.MethodBibliographic databases were searched to include preclinical and clinical studies demonstrating the therapeutic potential of buprenorphine and the involvement of the kappa opioid receptor (KOR) in mediating these effects.ResultsOriginal clinical studies examining the effectiveness of buprenorphine to treat depression were mixed. The majority of participants in the PTSD studies were males and suffer from chronic pain and/or substance use disorders. Nonetheless, these recent studies and analyses established proof of concept warranting farther investigations. Additionally, KOR likely mediates the antidepressant and some of the anxiolytic effects of buprenorphine. Still, it appears that the full spectrum of buprenorphine's beneficial effects might be due to activity at other opioid receptors as well.ConclusionsPharmaceuticals' abilities to treat medical conditions directly relates to their ability to act upon the endogenous biological systems related to the conditions. Thus, these recent findings are likely a reflection of the central role that the endogenous opioid system has in these mental illnesses. Further studies are necessary to study the involvement of endogenous opioid systems, and specifically KOR, in mediating buprenorphine's beneficial effects and the ability to treat these medical conditions while minimizing risks for misuse and diversion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|